{
    "name": "eculizumab",
    "comment": "Rx",
    "other_names": [
        "Soliris"
    ],
    "classes": [
        "Monoclonal Antibodies",
        "Complement Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/soliris-eculizumab-342875",
    "pregnancy": {
        "common": [
            "PNH and aHUS disease registries collect pregnancy outcomes in women exposed to eculizumab during pregnancy, contact www.pnhregistry.com or www.ahusregistry.com, or call (215)-616-3558",
            "In cases where gMG patients become pregnant, call (215)-616-3558",
            "There are no available data on eculizumab use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage",
            "Animal studies using a mouse analogue of the eculizumab molecule (murine anti-C5 antibody) showed increased rates of developmental abnormalities and an increased rate of dead and moribund offspring at doses 2-8 times the human dose",
            "Advise pregnant women of the potential risk to a fetus"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "There is no information regarding the presence of eculizumab in human milk, the effects on the breastfed infant, or the effects on milk production",
            "The developmental and health benefits of breastfeeding should be considered along with the motherâ€™s clinical need for eculizumab and any potential adverse effects on the breastfed child from eculizumab or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Life-threatening and fatal meningococcal infections have occurred in patients treated with Soliris; meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early",
                "Comply with most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccination in patients with complement deficiencies",
                "Immunize patients with meningococcal vaccines at least 2 weeks prior to administering first dose of the drug, unless the risks of delaying therapy outweigh risk of developing a meningococcal infection",
                "Vaccination reduces, but does not eliminate, risk of meningococcal infections; monitor patients for early signs of meningococcal infections and evaluate immediately if infection is suspected",
                "Available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS); prescribers must enroll in the program by telephone: 1-888-SOLIRIS (1- 888-765-4747) or at ",
                "www.solirisrems.com"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Documented hypersensitivity",
                "Unresolved serious Neisseria meningitidis infection or patients who are unvaccinated against N meningitidis (unless risk of delaying treatment outweigh the risk for meningococcal infection)"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Discontinue if being treated for serious meningococcal infection",
                "Supplement dose with plasma infusion or exchange",
                "Only administer as an IV infusion, do not give IVP or bolus (see Administration)",
                "Infusion-related reactions may occur; continue monitoring for 1 hr after completion of infusion"
            ],
            "specific": [
                {
                    "type": "Serious meningococcal infections risk and prevention",
                    "description": [
                        "Life-threatening and fatal meningococcal infections have occurred; the treatment increases a patient's susceptibility to serious meningococcal infections (septicemia and/or meningitis); therapy is associated with an approximate 2,000-fold increased risk of meningococcal disease in comparison to general U.S. population annual rate",
                        "Revaccinate for meningococcal disease in accordance with ACIP recommendations, considering the duration of therapy",
                        "Closely monitor patients for early signs and symptoms of meningococcal infection and evaluate patients immediately if infection suspected",
                        "Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early",
                        "Discontinue therapy in patients who are undergoing treatment for serious meningococcal infections"
                    ]
                },
                {
                    "type": "Other infections",
                    "description": [
                        "Serious infections with Neisseria species (other than N. meningitidis), including disseminated gonococcal infections, reported",
                        "The drug blocks terminal complement activation; therefore patients may have increased susceptibility to infections, especially with encapsulated bacteria",
                        "Additionally, Aspergillus infections have occurred in immunocompromised and neutropenic patients; children receiving therapy may be at increased risk of developing serious infections due to Streptococcus pneumoniae and Haemophilus influenzae type b (Hib)",
                        "Administer vaccinations for prevention of Streptococcus pneumoniae and Haemophilus influenzae type b (Hib) infections according to ACIP guidelines; use caution when administering therapy to patients with any systemic infection"
                    ]
                },
                {
                    "type": "Monitoring disease manifestations after therapy discontinuation",
                    "description": [
                        "Treatment discontinuation for PNH",
                        "Monitor patients after discontinuing Soliris for at least 8 weeks to detect hemolysis",
                        "Treatment Discontinuation for HUS",
                        "After discontinuing Soliris, monitor patients with aHUS for signs and symptoms of thrombotic microangiopathy (TMA) complications for at least 12 weeks",
                        "Clinical signs and symptoms of TMA include changes in mental status, seizures, angina, dyspnea, or thrombosis",
                        "The following changes in laboratory parameters may also identify a TMA complication, occurrence of two, or repeated measurement of any one of the following: a decrease in platelet count by 25% or more compared to baseline or the peak platelet count during treatment; an increase in serum creatinine by 25% or more compared to baseline or nadir during treatment; or, an increase in serum LDH by 25% or more over baseline or nadir during treatment",
                        "If TMA complications occur after therapy discontinuation, consider reinstitution of treatment, plasma therapy [plasmapheresis, plasma exchange, or fresh frozen plasma infusion (PE/PI)], or appropriate organ-specific supportive measures"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Headache",
            "percent": "44"
        },
        {
            "name": "Nasopharyngitis",
            "percent": "23"
        },
        {
            "name": "Back pain",
            "percent": "19"
        },
        {
            "name": "Nausea",
            "percent": "16"
        },
        {
            "name": "Cough",
            "percent": "12"
        },
        {
            "name": "Fatigue",
            "percent": "12"
        },
        {
            "name": "Hypertension",
            "percent": "47"
        },
        {
            "name": "Headache",
            "percent": "41"
        },
        {
            "name": "Diarrhea",
            "percent": "35"
        },
        {
            "name": "Anemia",
            "percent": "35"
        },
        {
            "name": "Vomiting",
            "percent": "29"
        },
        {
            "name": "Upper respiratory infection",
            "percent": "29"
        },
        {
            "name": "UTI",
            "percent": "24"
        },
        {
            "name": "Leukopenia",
            "percent": "24"
        },
        {
            "name": "Fatigue",
            "percent": "18"
        },
        {
            "name": "Peripheral edema",
            "percent": "18"
        },
        {
            "name": "Pyrexia",
            "percent": "18"
        },
        {
            "name": "Cough",
            "percent": "12"
        },
        {
            "name": "Headache",
            "percent": "26"
        },
        {
            "name": "Nasopharyngitis",
            "percent": "24"
        },
        {
            "name": "Diarrhea",
            "percent": "15"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "15"
        },
        {
            "name": "Arthralgia",
            "percent": "12"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "11"
        },
        {
            "name": "Constipation",
            "percent": "10"
        },
        {
            "name": "Flu",
            "percent": "8"
        },
        {
            "name": "like illness",
            "percent": "8"
        },
        {
            "name": "Myalgia",
            "percent": "8"
        },
        {
            "name": "Pain",
            "percent": "8"
        },
        {
            "name": "Various infections",
            "percent": "7"
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "HSV",
            "percent": null
        },
        {
            "name": "Serious or fatal meningococcal infections",
            "percent": null
        },
        {
            "name": "Pharyngolaryngeal pain",
            "percent": null
        },
        {
            "name": "Vertigo",
            "percent": null
        },
        {
            "name": "Pain in extremity",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Contusion",
            "percent": null
        },
        {
            "name": "Herpes simplex virus infections",
            "percent": null
        },
        {
            "name": "Peripheral edema",
            "percent": null
        },
        {
            "name": "Abdominal pain",
            "percent": null
        },
        {
            "name": "Pyrexia",
            "percent": null
        }
    ]
}